Drug Discovery Alliances offers a range of solid form capabilities to help facilitate the selection of a stable salt form and polymorph form as one moves a program into preclinical and clinical development. Stable forms are key to ensuring a successful development program. The following are the solid form capabilities offered by Drug Discovery Alliances:

Crystal Discovery Screen

The first step in solid form screening is to discover the first crystalline form with material amounts ranging from tens of milligrams up to grams of material. This is critical to have a full understanding of the physiochemical parameters of a development candidate.

Salt & Cocrystal Screens

DDA can help discover a crystalline form with improved properties. Salt and cocrystal screens can be used to identify new forms that can improve the properties of the drug candidate.

Polymorph Screen

DDA can screen for undiscovered polymorphs. Polymorphs are different crystal forms of the same molecule that can have different properties, such as solubility and stability. Identifying polymorphs is important to ensure that the most stable and suitable form is selected for further development.

Thermodynamic Stability Form Screen

DDA can probe thermodynamic form stability as a function of temperature and water activity. This is important to understand the stability of the drug candidate under different conditions.

Process Robustness Screen

DDA can screen the isolation process for form transition temperatures and activity points within the process space to ensure process robustness. This is important to ensure that the drug candidate can be manufactured consistently and reliably.

DDA offers a range of solid form capabilities to help facilitate the selection of a stable salt form and polymorph form as one moves a program into preclinical and clinical development. These capabilities are critical to ensure a successful development program.

Deborah Minor